• Calla Lily

  Led · Equity · Apr 2025

  Calla Lily Clinical Care is a UK-based medtech developing the Callavid, a tampon-shaped device designed to deliver progesterone more effectively and hygienically than vaginal pessaries. The Callavid is intended to reduce leakage, discomfort and anxiety associated with current progesterone administration. It targets women experiencing threatened miscarriage and early pregnancy complications; the article notes about 150,000 women in the UK are affected annually. The device is currently undergoing clinical trials. Trials will be led by Professor Siobhan Quenby MBE at University Hospitals Coventry and Warwickshire. The company has secured £1M in funding from the National Institute for Health and Care Research (NIHR).

• Presymptom Health

  Participated · Grant · Feb 2025

  Presymptom Health’s core product, InfectiClear, is an AI-driven diagnostic that analyses host RNA responses to detect infection—potentially up to three days earlier than pathogen-based methods. The test was trained and validated on 15 years of patient data and recent clinical trial results indicate it may have more than 95% accuracy at ruling out lower respiratory tract infection. The technology provides an early, highly sensitive signal for infection or sepsis, aiming to reduce delays and inaccuracies associated with traditional tests and help curb unnecessary antibiotic use. The company is making InfectiClear broadly compatible with multiple PCR platforms to ease NHS adoption, including point-of-care and lab workflows. Current funding announced is non-dilutive grant funding to accelerate platform compatibility and shorten test times to roughly 40–60 minutes. A six-month feasibility project with Health Innovation Oxford and Thames Valley will assess barriers to NHS adoption and the best rollout approach. Presymptom Health develops AI and machine-learning tools to identify infection and sepsis earlier than existing diagnostics, claiming detection up to three days before formal clinical diagnosis. The company analyses samples from a large biobank to extract signals that enable substantially faster detection of infections and sepsis. CEO Dr Iain Miller has emphasized that sepsis diagnostics have not advanced in more than a century and are often only possible once advanced symptoms and organ failure appear. The startup cites that each hour sepsis goes untreated raises mortality by about 10%, and notes nearly 48,000 sepsis deaths annually in Britain. Financially, Presymptom Health has secured external backing, including a recent raise reported in the article. The technology is positioned as an AI-driven improvement to clinical workflows for earlier intervention.

• Laennec AI

  Participated · Seed · Nov 2024

  Laennec AI develops a mobile platform that transforms smartphones into AI-driven digital stethoscopes to detect, prevent, and manage asthma exacerbations at home. Founded in 2022 by Dr. Jase John and Dr. Arathy Varghese, the company embeds advanced algorithms into a user-friendly app to enable remote monitoring and clinician oversight. Its product supports virtual consultations, continuous remote monitoring, and guided self-care aimed at reducing emergency hospital visits and improving chronic disease outcomes. Laennec positions its technology to improve access in underserved areas and reduce healthcare inequalities by making diagnostic tools more affordable and portable. The company has begun commercial and development activities backed by a recent funding round and grant support to accelerate device development and scale deployment. It is actively engaging healthcare providers, clinicians, and research institutions for partnerships to advance remote monitoring and patient-led care.

No current team members are available.